5VA Stock Overview
A clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Vaxcyte, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$82.00 |
| 52 Week High | US$108.00 |
| 52 Week Low | US$54.50 |
| Beta | 0.94 |
| 1 Month Change | -1.80% |
| 3 Month Change | -17.59% |
| 1 Year Change | 51.85% |
| 3 Year Change | 286.79% |
| 5 Year Change | n/a |
| Change since IPO | 86.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5VA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.6% | -2.6% | -2.0% |
| 1Y | 51.9% | -13.2% | 6.8% |
Return vs Industry: 5VA exceeded the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: 5VA exceeded the German Market which returned 6.9% over the past year.
Price Volatility
| 5VA volatility | |
|---|---|
| 5VA Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5VA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 5VA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 254 | Grant Pickering | vaxcyte.com |
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Vaxcyte, Inc. Fundamentals Summary
| 5VA fundamental statistics | |
|---|---|
| Market cap | €10.36b |
| Earnings (TTM) | -€487.80m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-21.4x
P/E RatioIs 5VA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5VA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$75.00m |
| Gross Profit | -US$75.00m |
| Other Expenses | US$432.65m |
| Earnings | -US$507.65m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.07 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 5VA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 17:59 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vaxcyte, Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Thomas Shrader | BTIG |
| Louise Chen | Cantor Fitzgerald & Co. |